Haemonetics Corporation shares jumped 16.3% on Tuesday after the company disclosed a non-exclusive supply agreement with CSL Plasma Inc. The arrangement, executed on August 14, 2026, permits CSL Plasma to employ Haemonetics' NexSys PCS devices equipped with Persona PLUS technology and to procure associated disposable components within the United States.
The contract does not impose minimum purchase commitments on CSL, and Haemonetics said CSL is expected to convert a portion of its U.S. plasma collection centers to the company's hardware and disposables. The precise scope of that transition and the schedule for rolling out the devices have not been determined.
Given the absence of firm implementation timelines and detailed rollout plans from CSL, Haemonetics is maintaining its previously issued fiscal 2027 guidance and is not revising outlook figures at this time. The company indicated it plans to provide an update on how the agreement is anticipated to affect fiscal 2027 financials during its second fiscal quarter earnings call, scheduled for November 2026.
Management described the agreement as a potential avenue for Haemonetics to expand within the plasma collection market, though it emphasized that the ultimate financial implications depend on CSL's decisions about how many centers to transition and when to do so. Until CSL provides more definitive implementation information, the magnitude and timing of revenue and margin effects for Haemonetics remain unclear.
What this means for markets and sectors
- Medical devices and healthcare services: The agreement represents a potential commercial expansion for a medical-device supplier into plasma collection, a specific niche within healthcare services.
- Public markets: The announcement produced an immediate positive reaction in Haemonetics’ stock price, reflecting investor interest in potential growth opportunities tied to the supply deal.
- Supply chain and procurement: Because the deal is non-exclusive and lacks minimum commitments, it affects procurement flexibility for plasma collectors and for Haemonetics’ revenue visibility.
Outlook and next steps
Haemonetics will monitor CSL’s implementation choices and aims to report an anticipated impact on fiscal 2027 results during its November 2026 second fiscal quarter earnings call. Until then, the market will rely on future disclosures for clarity about the agreement’s contribution to sales and earnings.